속보 • May 15
Insulet Earnings and Revenue Top Estimates With Omnipod Growth and Global Expansion Insulet reported Q1 2026 earnings per share of $1.42, about 20% above analyst estimates, on revenue of $761.7 million that was nearly 34% higher year over year.
Omnipod 5 adoption across the U.S. and internationally was a key driver, with international Omnipod revenue growing over 59% and new launches in regions such as the Middle East.
The company lifted its 2026 constant-currency revenue growth guidance to a range of 21% to 23%, expanded adjusted operating margins to about 18.8%, and continues to invest in a fully closed-loop system for type 2 diabetes targeted for a planned 2027 FDA 510(k) filing, while absorbing a $12 million expense impact from a voluntary medical device correction.
The combination of stronger-than-expected earnings, higher revenue guidance and margin expansion points to solid execution around the Omnipod franchise and geographic expansion.
Investors may want to watch progress on the type 2 diabetes closed-loop program and any further device-related corrections, since both could influence future growth opportunities and cost trends. Price Target Changed • May 07
Price target decreased by 23% to US$252 Down from US$326, the current price target is an average from 23 analysts. New target price is 57% above last closing price of US$160. Stock is down 38% over the past year. The company is forecast to post earnings per share of US$6.13 for next year compared to US$3.51 last year. Reported Earnings • May 06
First quarter 2026 earnings: EPS and revenues exceed analyst expectations First quarter 2026 results: EPS: US$1.30 (up from US$0.50 in 1Q 2025). Revenue: US$761.7m (up 34% from 1Q 2025). Net income: US$91.1m (up 157% from 1Q 2025). Profit margin: 12% (up from 6.2% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.3%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. 공시 • May 05
Insulet Corporation Initiates Evolve Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes Insulet Corporation has enrolled the first participant in a pivotal study for its fully closed-loop (FCL) automated insulin delivery (AID) system for type 2 diabetes (T2D). FCL for T2D is a breakthrough innovation intended to further improve glycemic outcomes with less burden for users across diverse care settings. That includes eliminating user interactions for bolusing and mealtime announcements for people with T2D as well as settings to start and onboard. Advancing AID Through a Fully Closed Loop System: The EVOLVE clinical study is a multi-center randomized control trial actively enrolling up to 350 adults across a maximum of 40 U.S. sites. The participants are between 18 – 75 years of age, living with T2D and using insulin (basal-bolus or basal-only). The Company received Investigational Device Exemption (IDE) approval in March 2026 from the U.S. Food and Drug Administration (FDA). The Company aims to remove barriers and expand access to AID, particularly in primary care, where approximately 70% of people with T2D are managed. By streamlining onboarding and training and eliminating start-up settings, Insulet’s FCL for T2D is designed to reduce workload and support healthcare professionals across specialties and care settings. The EVOLVE Pivotal Study follows a three-part series of feasibility studies to support the development of Insulet’s FCL AID system. The Company presented promising feasibility results at the 19International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Barcelona, Spain, including a 24% time in range (TIR) improvement, for an average of 68%, over standard injection therapy. In 2024, Insulet shared results from its landmark SECURE-T2D pivotal trial, demonstrating improved glycemic outcomes with Omnipod 5 compared with prior insulin injection or pump therapy in adults with T2D. Participants experienced a reduction in HbA1c from 8.2% to 7.4% and a 20% increase in TIR– from 45% to 66% or 4.8 hours daily. With these results, Insulet was the first company to receive 510(k) clearance for an AID system, Omnipod 5, for adults with T2D. Since then, the Company has seen impressive adoption rates and real-world evidence of glycemic improvements including more than 80% TIR with optimized settings for people with T2D using Omnipod 5. While Insulet’s type 2 prescriber base in the U.S. grew by more than 60% in 2025 to more than 6,500 clinicians, AID adoption remains well below 5% for the estimated 5.5 million people with T2D who require insulin. Insulet is committed to continuing to expand adoption of AID for this population, as recommended by the American Diabetes Association’s 2026 Standards of Care. The Company plans to submit a 510(k) filing to the FDA in 2027 and launch its FCL AID system for T2D in 2028. The FCL AID System is an investigational device. Limited by Federal (or United States) law to investigational use. This product has not been reviewed by the FDA or any other regulatory agency. Venkatraman S, et al. Trends and Disparities in Glycemic Control and Severe Hyperglycemia Among U.S. Adults with Diabetes Using Insulin, 1988-22020. JAMA Netw Open. 2022 Dec 1;5(12). The EVOLVE study will evaluate a new fully closed-looped AID system for Type 2 diabetes. Retrospective RWE data on file. 2025. Results shown for T2D users with optimized settings including sufficient CGM data (=75% of days with =220 readings), =90% time in Automated Mode, =3 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI =1500, I:C Ratio x TDI =350. RF-062025-00014. Valuation Update With 7 Day Price Move • Apr 29
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to US$160, the stock trades at a forward P/E ratio of 25x. Average trailing P/E is 24x in the Medical Equipment industry in the US. Total loss to shareholders of 50% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$289 per share. 공시 • Apr 07
Insulet Corporation, Annual General Meeting, May 20, 2026 Insulet Corporation, Annual General Meeting, May 20, 2026. 공시 • Apr 01
Insulet Corporation to Report Q1, 2026 Results on May 06, 2026 Insulet Corporation announced that they will report Q1, 2026 results Pre-Market on May 06, 2026 공시 • Mar 30
Insulet Corporation Appoints Mike Panos as Executive Vice President and Chief Commercial Officer, Effective March 30, 2026 Insulet Corporation announced the appointment of Mike Panos as Executive Vice President, Chief Commercial Officer, effective March 30, 2026. In this role, Mr. Panos will lead Insulet’s global commercial organization, reporting to President and Chief Executive Officer Ashley McEvoy. He will also be a member of the Executive Leadership Team. Mr. Panos brings 30 years of commercial leadership experience in the medical technology sector, most recently serving as Leader, Sales Excellence at Stryker Corporation. Over his three-decade career at Stryker, he held multiple senior leadership roles, including President of the Trauma and Extremities Division and President of North America and Global R&D. He is widely recognized for developing top talent, instilling rigorous commercial discipline, and leading large, global teams to deliver both top-line growth and operational performance. Mr. Panos is a Boston College graduate and long-time Boston-area resident, bringing deep ties to the region and local leadership experience to Insulet’s Massachusetts-based team. At Insulet, Mr. Panos will lead the Company’s global commercial organization, with responsibility for driving commercial strategy and execution across geographies, expanding market access, and strengthening capabilities to support continued growth and reach, including expanding into new patient populations and care settings. 공시 • Mar 13
Insulet Corporation Initiates Voluntary Medical Device Correction For Certain Omnipod 5 Pods In The U.S Insulet Corporation initiated a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods after identifying a manufacturing issue through its ongoing product monitoring. This action applies to specific identified lots distributed in the United States, and all other Omnipod 5 Pods and Omnipod products remain safe to use. Insulet identified that certain Pods from specific lots may have a small tear in the internal tubing that delivers insulin. If this occurs, insulin may leak inside the Pod instead of being fully infused into the body as intended. If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of insulin. In the most severe cases, prolonged and persistent high blood glucose levels can lead to diabetic ketoacidosis (DKA), a serious medical condition that requires prompt medical treatment. Insulet has received 18 reports of serious adverse events associated with high blood glucose levels, including hospitalization and DKA. No deaths have been reported. This issue does not affect continuous glucose monitoring (CGM) systems or CGM readings. Following its investigation, Insulet has implemented updates to its manufacturing processes and quality controls to strengthen detection and prevention and further support the integrity of its products. The Pods involved in this correction represent approximately 1.5% of annual Omnipod 5 pod production globally. Insulet continues to manufacture and ship Omnipod 5 Pods and does not anticipate disruption to customer shipments, product availability, or new patient starts. The U.S. Food and Drug Administration has been notified of this action. Customers should visit omnipod.com/check-pods to confirm whether their Pod lot number is included in this voluntary Medical Device Correction and request replacement Pods at no cost. If a Pod from an affected lot is currently in use, customers should discontinue use and replace it with a Pod from an unaffected lot. Customers who have questions or need assistance may contact Insulet Product Support at 1-800-641-2049 (available 24/7) or use the live agent chat at omnipod.com/current-podders. 공시 • Mar 12
Insulet Corporation Presents Promising Study Results For Fully Closed-Loop Automated Insulin Delivery System For Adults With Type 2 Diabetes Insulet Corporation shared new clinical evidence related to the development of its first fully closed-loop automated insulin delivery system for type 2 diabetes. Outcomes from EVOLUTION 2 study include 68% time in range with no boluses. Diverse multicenter feasibility study highlights the promise of future Omnipod innovation to address unmet needs, improve outcomes, and redefine user and clinician experience. Presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes in Barcelona, Spain, EVOLUTION 2 is the second in a series of feasibility studies supporting the development of an Omnipod fully closed-loop system. This multicenter feasibility study was designed to drive rapid innovation, allowing investigators to evaluate multiple versions of the algorithm to support continued fully closed-loop system development. It included 24 adults in a highly diverse cohort from New Zealand, aged 16-70 years with type 2 diabetes using insulin (basal-bolus or basal-only, pumps or injections with HbA1c under 12.0%). The participants had lived with type 2 diabetes for an average of 16 years. When using the final algorithm version of fully closed-loop with no boluses, the participants’ time in range increased to an average of 68%, a 24% improvement over standard injection therapy. Time Below Range remained very low, with a median of 0.14% below 70 mg/dL—well under the American Diabetes Association’s recommended threshold of less than 4%. No severe hypoglycemia or diabetic ketoacidosis events were observed. Users experienced improved glycemic outcomes without compromising on low glucose events. The benefits were observed across a diverse set of participant characteristics including sex, ethnicity, baseline HbA1c, and body mass index. More than 90% of participants chose to continue into the ongoing extension phase, showing strong interest and positive experiences with the fully closed-loop system. EVOLUTION 2 builds on the 2024 EVOLUTION 1 feasibility study, which was the first evaluation of the Omnipod fully closed-loop algorithm in adults with type 2 diabetes. Participants in the EVOLUTION 1 study experienced significant improvements in time in range, from 52% to 65%, without boluses, representing more than three additional hours per day in target range with minimal hypoglycemia. Insulet used these results to fine-tune the algorithm design, focusing on further simplifying the user experience and laying the groundwork for additional improvements studied with EVOLUTION 2. The company plans to start its pivotal study (EVOLVE) in 2026 to support a 510(k) filing in 2027 and a commercial launch in 2028. 공시 • Mar 10
Insulet Corporation Presents Evolution 2 Results and Demonstrates Omnipod Fully Closed-Loop System for Adults with Type 2 Diabetes Insulet Corporation announced to present new clinical evidence related to its first fully closed-loop (FCL) automated insulin delivery (AID) system for type 2 diabetes (T2D) at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), taking place March 11 – 14, 2026 in Barcelona, Spain, and online. The EVOLUTION 2 study results will be presented at Insulet’s symposium by Dr. Martin de Bock, Professor and Pediatric Endocrinologist at the University of Otago, Christchurch in New Zealand. This study is part of a series of EVOLUTION feasibility studies to test the safety and efficacy of the T2D FCL System which eliminates burden from dosing decisions and simplifies the provider experience. The symposium, entitled “Omnipod: Breakthrough Simplicity. Better Control. Fully Closing the Loop.” will take place on Wednesday, March 11 from 2:40 – 4:10 p.m. CET in Hall 112. In addition to Dr. de Bock’s presentation of EVOLUTION 2, the symposium will focus on glycemic improvements with Omnipod 5 and the importance of AID technology as standard of care for people with diabetes. A total of seven posters and presentations on the Omnipod 5 System, the Omnipod DASH Insulin Management System, and future innovations will be presented at ATTD. Oral Presentations include: Settings Associated with Optimal Outcomes with the Omnipod 5 Automated Insulin Delivery System: Evidence from Real-World Users with Type 2 Diabetes with Dr. Grazia Aleppo: 10:30 – 10:40 a.m. CET, Hall 115; Glycemic Outcomes with the Omnipod 5 Automated Insulin Delivery System in Users with Low Insulin Requirements (fewer than 5 units/day): Evidence from Real-World Users with Dr. Lori Laffel: 13:45 – 13:55 p.m. CET, Hall 113; Settings Associated with Optimal Outcomes with the Omnipod 5 Automated Insulin Delivery System: Evidence from Real-World Users with Type 1 Diabetes with Dr. Gregory Forlenza: 13:55 – 14:05 p.m. CET, Hall 113; Glycemic Outcomes with the Omnipod 5 Automated Insulin Delivery System in Infants and Toddlers with Dr. Jamie Wood: 14:05 – 14:15 p.m. CET, Hall 113; Tubed or Tubeless Insulin Pumps? A Retrospective Real-World Analysis of National French Health Data with Pr. Bogdan Nicolescu-Catargi: 14:45 p.m., Hall 212. Poster Presentations include: e-Poster EP070 – Outpatient Evaluation of a Next-Generation Fully Closed-Loop Algorithm for Omnipod in Adults with Type 2 Diabetes with Dr. Martin de Bock; e-Poster EP082 – Improved Health-related Quality of Life for Adults with Type 1 Diabetes: Impact of Tubeless Therapy on the Implementation Plan for Automated Insulin Delivery in England with Dr. Jackie Elliott. e-Poster presentations will be available throughout the entire conference. Clinical experts will offer hands-on Omnipod product demonstrations to conference attendees at the Omnipod booth (38), offering attendees the chance to experience Omnipod 5. An immersive, multi-media experience inside an inflatable dome will also be available on Wednesday evening and Thursday during exhibit hall hours. The dome will include a 180-degree video screen and other sensory displays to tell Insulet’s story and showcase how Omnipod 5 is transforming diabetes management. Throughout the show, Insulet will record episodes for its Beyond the Bolus, TypeCast, and Within Range podcasts, featuring interviews with various healthcare providers, thought leaders, and Omnipod users. Visitors will be able to listen to these conversations live from a dedicated space next to the main Omnipod exhibit. Sr. Research Analyst Jeff Johnson of Baird will be hosting a webcast featuring Dr. Ly on Friday, March 13, at 3:00 PM CET. The interview will feature a recap of highlights, new clinical data, and updates from ATTD. Recent Insider Transactions • Feb 26
CEO, President & Director recently bought US$1.0m worth of stock On the 20th of February, Ashley McEvoy bought around 4k shares on-market at roughly US$239 per share. This transaction increased Ashley's direct individual holding by 54x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Ashley's only on-market trade for the last 12 months. Reported Earnings • Feb 19
Full year 2025 earnings: Revenues and EPS in line with analyst expectations Full year 2025 results: EPS: US$3.51 (down from US$5.97 in FY 2024). Revenue: US$2.71b (up 31% from FY 2024). Net income: US$247.1m (down 41% from FY 2024). Profit margin: 9.1% (down from 20% in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. 공시 • Feb 18
Insulet Corporation Provides Earnings Guidance for the First Quarter Ending March 31, 2026 and Year Ending December 31, 2026 Insulet Corporation provided earnings guidance for the first quarter ending March 31, 2026 and year ending December 31, 2026. for the quarter, the company expects GAAP revenue growth of 21% - 23%.
for the year, the company expects GAAP revenue growth of 27% - 29%. 공시 • Feb 05
Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care Insulet Corporation announced its transformative Omnipod 5 Automated Insulin Delivery (AID) System is now available in the Middle East - including Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates (UAE). The Company is making the announcement at the 16th edition of the Emirates Diabetes and Endocrine Congress (EDEC) in Dubai. The Omnipod 5 System simplifies diabetes management and has demonstrated strong glycemic outcomes, including improved time in range and lowering HbA1c, by automatically adjusting insulin delivery every five minutes and eliminating the need for multiple daily injections (MDI)2. The waterproof3, discreet, and wearable Omnipod 5 is the first tubeless AID system that communicates with a sensor and proactively corrects for highs and helps to protect against lows, day and night4,5. Omnipod 5 is indicated for individuals aged two years and older with type 1 diabetes and compatible with the Abbott FreeStyle Libre 2 Plus sensor and the Dexcom G7 sensor in Saudi Arabia, Kuwait, and the UAE, and with the Dexcom G 7 sensor in Qatar. Omnipod Discover: Diabetes Data Management - Simplified: Insulet is also launching Omnipod Discover, a proprietary and retrospective data analytics and reporting platform designed for Omnipod 5 users, their caregivers, and healthcare providers. Easy to access, Omnipod Discover streamlines the analysis of glucose and insulin delivery data and delivers meaningful insights -- transforming complex information into clear, relevant trends and recommendations that inform diabetes management. Its web-based intuitive display shows how the Omnipod 5 algorithm automates insulin delivery, enabling understanding of trends to make decisions confidently. Users can also access their data with insights in a simplified way that empowers them to understand and manage their diabetes. Omnipod Discover is being introduced in these Middle Eastern markets first, with plans to expand to other countries where Omnipod 5 is available. With these new market launches, Omnipod 5 is now available globally in 19 countries with plans to launch in Spain (a new market for Insulet) in 2026, followed by Greece and Croatia in the first half of 2027. Buy Or Sell Opportunity • Jan 28
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 17% to US$258. The fair value is estimated to be US$324, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 62%. For the next 3 years, revenue is forecast to grow by 16% per annum. Earnings are also forecast to grow by 25% per annum over the same time period. 공시 • Jan 09
Insulet Corporation to Report Q4, 2025 Results on Feb 18, 2026 Insulet Corporation announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Feb 18, 2026 공시 • Dec 04
Insulet Corporation Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements That Redefine Insulin Delivery and Simplify the Pod Experience Insulet Corporation announced it has received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to the Omnipod 5 algorithm set a new benchmark in tubeless diabetes technology by offering a lower 100 mg/dL Target Glucose option and a more seamless automated experience. More Flexibility with a Lower Target Glucose Setting: The new 100 mg/dL Target GlUCose expands Omnipod 5's customization range to six settings between 100-150 mg/dL in 10 mg/dL increments. This flexibility allows healthcare providers to tailor insulin delivery more precisely, supporting individuals seeking tighter glucose management or those striving to meet specific glucose goals. It also directly impacts automated insulin delivery and improves the algorithm's responsiveness. Real world evidence has shown that lowering the glucose target is associated with increased time in range, with no clinically meaningful change in Time Below Range1 (TBR). In addition, the upgraded Omnipod 5 algorithm helps users stay in Automated Mode with fewer interruptions, even during prolonged high glucose events. These advancements are designed to deliver strong clinical results with increased flexibility and greater ease of use, with fewer interruptions to daily life. The updates to the Omnipod5 algorithm are anticipated to launch in the United States in the first half of 2026, where Omnipod 5 is cleared for people aged 2 and older with type 1 and aged 18 and older with type 2 diabetes. Reported Earnings • Nov 06
Third quarter 2025 earnings: EPS and revenues exceed analyst expectations Third quarter 2025 results: EPS: US$1.25 (up from US$1.11 in 3Q 2024). Revenue: US$706.3m (up 30% from 3Q 2024). Net income: US$87.6m (up 13% from 3Q 2024). Profit margin: 12% (down from 14% in 3Q 2024). Revenue exceeded analyst estimates by 4.0%. Earnings per share (EPS) also surpassed analyst estimates by 8.2%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. 공시 • Nov 06
Insulet Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year Ending December 31, 2025 Insulet Corporation provided revenue guidance for the fourth quarter and full year ending December 31, 2025. For the quarter, the company expects total omnipod revenue in constant currency 27%-30% as compared to 25%-28% from a year ago.
For the full year, the company expects revenue in constant currency of 28%-29% as compared to 24%-27% from a year ago. Buy Or Sell Opportunity • Nov 04
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 15% to US$320. The fair value is estimated to be US$267, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 76%. For the next 3 years, revenue is forecast to grow by 15% per annum. Earnings are also forecast to grow by 25% per annum over the same time period. 공시 • Oct 23
Insulet Corporation Appoints Robert L. Huffines to the Board of Directors and Audit Committee, Effective October 31, 2025 On October 21, 2025, Insulet Corporation announced the appointment of Robert L. Huffines, a former Global Chair of Investment Banking at JP Morgan Chase & Co., to the Company’s board of directors, as a Class II director, effective October 31, 2025. Mr. Huffines joins the board as an independent director and will serve on the board’s Audit Committee. Mr. Huffines joined J.P. Morgan in 1992 in the Mergers and Acquisitions group, with a focus on the healthcare industry. From 2002 to 2010, he served as co-head of the company’s global healthcare investment banking group, and, from 2011 to 2020, Mr. Huffines served as JP Morgan Chase’s Vice Chairman of Investment Banking. From 2020 to 2024, Mr. Huffines was the company’s Global Chair of Investment Banking and a member of the Executive Committee. Prior to joining J.P. Morgan, he worked at Alex Brown & Sons, specializing in equity financing and advisory assignments for emerging growth companies. Mr. Huffines and his wife, Lisa Huffines, founded The Forest Group Inc., a not-for-profit organization focused on improving the mental health of children in underserved communities. Mr. Huffines currently serves on the boards of directors of Nextech Invest Ltd., Eikon Therapeutics, and the Hastings Center for Biomedical Ethics. He also served as a director of Walgreens Boots Alliance until its sale in August 2025. Mr. Huffines earned his M.B.A. from the Darden School of Business at the University of Virginia, where he received the Faculty Award for academic excellence. He pursued his baccalaureate education at the University of North Carolina, where he majored in English and Economics. Buy Or Sell Opportunity • Sep 18
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 10% to US$334. The fair value is estimated to be US$277, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 76%. For the next 3 years, revenue is forecast to grow by 15% per annum. Earnings are also forecast to grow by 24% per annum over the same time period. 공시 • Aug 26
Insulet Corporation Announces Executive Appointments Insulet Corporation announced the appointment of Eric Benjamin to Chief Operating Officer effective immediately. The Company also announced the appointment of Manoj Raghunandanan as Chief Growth Officer. In this expanded role, Mr. Benjamin will lead Insulet’s end-to-end growth and innovation engine, setting strategy and guiding execution across new products, new markets, and commercial expansion. He will oversee Strategy & Business Development, the Office of the Chief Technology Officer, Research & Development, and a newly-created Growth organization, ensuring strong alignment across teams to drive growth and advance the Company’s strategic priorities. Since joining Insulet in 2015, Mr. Benjamin has been instrumental in transforming the Company into an innovation-driven leader in diabetes care. Through a series of progressive leadership roles, he has strengthened supply chain resilience, launched Omnipod DASH® and Omnipod 5®, expanded Insulet’s reach into the type 2 diabetes market, and digitized the customer experience to improve customer engagement and satisfaction. Most recently, as Executive Vice President, Chief Product & Customer Experience Officer, Mr. Benjamin directed global product strategy, customer experience, commercial execution, and Insulet’s innovation roadmap. With the expansion of Mr. Benjamin’s remit, Insulet also announced the appointment of Manoj Raghunandanan as Chief Growth Officer. Mr. Raghunandanan brings more than 20 years of global consumer health leadership experience at Kenvue (formerly Johnson & Johnson Consumer Health). He most recently served as general manager of their Northern European business and previously sat on the Executive Committee for five years overseeing a $6 billion global OTC portfolio. He has held senior leadership roles in the U.S., Europe, and Asia, building high-performing teams, driving commercial excellence, and scaling global brands. Mr. Raghunandanan will lead Insulet’s newly-formed Growth organization, developing global strategy, overseeing demand generation, accelerating commercial capabilities, and stewarding the global brand and customer experience to accelerate the Company’s next chapter of global growth. Recent Insider Transactions Derivative • Aug 22
Executive VP notifies of intention to sell stock Eric Benjamin intends to sell 4k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of August. If the sale is conducted around the recent share price of US$332, it would amount to US$1.4m. Since December 2024, Eric's direct individual holding has increased from 12.64k shares to 14.73k. Company insiders have collectively sold US$10m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Aug 08
Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2025 results: EPS: US$0.32 (down from US$2.69 in 2Q 2024). Revenue: US$649.1m (up 33% from 2Q 2024). Net income: US$22.5m (down 88% from 2Q 2024). Profit margin: 3.5% (down from 39% in 2Q 2024). Revenue exceeded analyst estimates by 6.0%. Earnings per share (EPS) missed analyst estimates by 66%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. 공시 • Jul 08
Insulet Corporation to Report Q2, 2025 Results on Aug 07, 2025 Insulet Corporation announced that they will report Q2, 2025 results Pre-Market on Aug 07, 2025 공시 • Jun 10
Insulet Corporation's Omnipod 5 App for Iphone with Dexcom G7 Integration Now Available to All U.S. Users Insulet Corporation announced that the Omnipod®? 5 App for iPhone is now compatible with the Dexcom G7 Continuous Glucose Monitoring (CGM) System. With this latest integration, the Omnipod 5 Automated Insulin Delivery (AID) System combines the benefits of tubeless AID and Dexcom's latest diabetes management technology, all conveniently controlled from an iPhone. Omnipod 5 proactively adjusts insulin delivery every five minutes, autoc incorrects for high glucose, and helps protect against lows, day and night--even while sleep. The Omnipod 5 App for iPhone, available in the U.S., offers full control of Omnipod 5 including the ability to bolus, change a Pod, adjust settings, access valuable insights, and more. The Omnipod 5 app with Dexcom G7 and Dexcom G6 compatibility is now available for download on the Apple App Store. Reported Earnings • May 10
First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2025 results: EPS: US$0.50 (down from US$0.74 in 1Q 2024). Revenue: US$569.0m (up 29% from 1Q 2024). Net income: US$35.4m (down 31% from 1Q 2024). Profit margin: 6.2% (down from 12% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 4.7%. Earnings per share (EPS) missed analyst estimates by 37%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. 공시 • May 01
Insulet Corporation, Annual General Meeting, May 22, 2025 Insulet Corporation, Annual General Meeting, May 22, 2025. 공시 • Apr 07
Insulet Corporation Launches Omnipod 5 Automated Insulin Delivery System in Canada Insulet Corporation announced that Omnipod 5 is now commercially available in Canada. Omnipod 5 is the first tubeless, waterproof Automated Insulin Delivery (AID) System approved for use in Canada for people with type 1 diabetes ages two years and above. The Omnipod 5 AID System is compatible in Canada with the Dexcom G6 and Dexcom G7 Continuous Glucose Monitoring (CGM) Systems to continuously adapt and automatically deliver insulin according to the user's personal needs, simplifying diabetes for patients. Public reimbursement for Omnipod 5 is currently in place in Ontario and Nova Scotia. Insulet is actively working to expand Omnipod 5 coverage across additional provinces and territories throughout the country. Living with diabetes is very burdensome and often involves constant monitoring and multiple daily injections, or dealing with cumbersome pumps with tubing, all of which can contribute to the constant stress of managing glucose levels. In fact, people with diabetes make an estimated 180 more decisions each day about their health than someone without diabetes4. Omnipod 5 is designed to make living with diabetes simpler, delivering exceptional ease of use; it automatically manages glucose levels, eliminating multiple daily injections, insulin pump tubing or routine fingersticks, providing a seamless and intuitive System that adjusts insulin doses automatically based on real-time glucose readings. 공시 • Apr 03
Insulet Corporation to Report Q1, 2025 Results on May 08, 2025 Insulet Corporation announced that they will report Q1, 2025 results at 4:00 PM, US Eastern Standard Time on May 08, 2025 Price Target Changed • Feb 28
Price target increased by 7.0% to US$313 Up from US$292, the current price target is an average from 22 analysts. New target price is 15% above last closing price of US$272. Stock is up 61% over the past year. The company is forecast to post earnings per share of US$4.24 for next year compared to US$5.97 last year. Reported Earnings • Feb 21
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: EPS: US$5.97 (up from US$2.96 in FY 2023). Revenue: US$2.07b (up 22% from FY 2023). Net income: US$418.3m (up 103% from FY 2023). Profit margin: 20% (up from 12% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.3%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. 공시 • Feb 21
Insulet Corporation Provides Revenue Guidance for the First Quarter Ending March 31, 2025 and Full Year Ending December 31, 2025 Insulet Corporation provided revenue guidance for the first quarter ending March 31, 2025 and full year ending December 31, 2025. For the quarter, the company expects revenue growth of 22% to 25%. Revenue growth ranges by product line are: Total Omnipod of 17% to 21% - U.S. Omnipod of 16% to 20% and International Omnipod of 22% to 26%; and Drug Delivery of (55)% to (45)%.
For the year, the Company expects revenue growth of 16% to 20%. Revenue growth ranges by product line are: Total Omnipod of 23% to 26% - U.S. Omnipod of 21% to 24% and International Omnipod of 28% to 31%; and Drug Delivery of (10)% to (5)%. Recent Insider Transactions Derivative • Jan 22
Executive VP notifies of intention to sell stock Eric Benjamin intends to sell 12k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of January. If the sale is conducted around the recent share price of US$280, it would amount to US$3.5m. Since March 2024, Eric's direct individual holding has decreased from 16.87k shares to 12.64k. Company insiders have collectively sold US$8.4m more than they bought, via options and on-market transactions in the last 12 months. Buy Or Sell Opportunity • Jan 17
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 17% to US$276. The fair value is estimated to be US$228, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 5.9% per annum over the same time period. 공시 • Jan 14
Insulet Launches Revolutionary Omnipod 5 in Five More Countries in Europe Insulet Corporation announced the Omnipod 5 Automated Insulin Delivery System is now commercially available in five more countries--Italy, Denmark, Finland, Norway, and Sweden. Omnipod 5 is now available with both Abbott's FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring (CGM) sensor compatibility. Indicated for individuals aged two years and older with type 1 diabetes, Omnipod 5 is the first and only tubeless automated insulin delivery (AID) system integrated with both leading CGM sensor brands. Omnipod is recognized as the number one insulin pump for new pump users in Europe1. Omnipod 5 is also the number one prescribed AID system in the U.S.2 and the first tubeless, waterproof3 AID system with proactive Glucose control designed to deliver exceptional ease of use. It was first introduced in the U.S. in 2022, integrated with Dexcom G6, and has demonstrated strong clinical results with real world evidence including lower A1c and improved time in range, while maintaining low time in hypoglycemia. Sensor integration with Abbott's FreeStyle Libre 2 plus and Dexcom G6 allows many users to benefit from Omnipod 5 with their sensor of choice. It also gives prescribers more flexibility when recommending a sensor for their patients, making it fast and easy to start AID therapy with Omnipod 5. 공시 • Jan 10
Insulet Corporation to Report Q4, 2024 Results on Feb 20, 2025 Insulet Corporation announced that they will report Q4, 2024 results After-Market on Feb 20, 2025 Recent Insider Transactions • Dec 19
Executive VP recently sold US$1.2m worth of stock On the 16th of December, Eric Benjamin sold around 4k shares on-market at roughly US$268 per share. This transaction amounted to 26% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$6.1m more than they bought in the last 12 months. Recent Insider Transactions Derivative • Dec 17
Executive VP notifies of intention to sell stock Eric Benjamin intends to sell 4k shares in the next 90 days after lodging an Intent To Sell Form on the 16th of December. If the sale is conducted around the recent share price of US$268, it would amount to US$1.2m. Since March 2024, Eric has owned 16.87k shares directly. Company insiders have collectively sold US$7.2m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Nov 08
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: EPS: US$1.11 (up from US$0.74 in 3Q 2023). Revenue: US$543.9m (up 26% from 3Q 2023). Net income: US$77.5m (up 49% from 3Q 2023). Profit margin: 14% (up from 12% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.7%. Earnings per share (EPS) also surpassed analyst estimates by 37%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. 
